Continuous use of either SGLT-2i or DPP-4i in people with T2 diabetes not associated with increased risk of peripheral arterial disease. The 48-month data dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

Dr Jon Hazlehurst talking about the challenge of weight management in patients with diabetes.

With the availability of continuous glucose monitors, time in range has supplanted a1c in diabetes management. But what about time-in-tight-range (TITR)? 🤔 TITR might be a more sensitive marker for microvascular complication risk than TIR or HbA1c, especially when TIR is more

The South Asian Health Foundation UK 2025 conference 16th and 17th October in Birmingham. Initial planning meeting and #dukpc2025 SAHF.ORG.UK Prof Kamlesh Khunti Sarah Ali FRSA 👩🏻‍⚕️👩🏻‍🎨 Shivani Misra Srikanth Bellary Ponnusamy Saravanan Muhammad Ali Karamat

Great talk on Ramadan in Diabetes Prof. Wasim Hanif Diabetes UK #dukpc2025 -#Ramadan

An update on ABCD Diabetes activity by Dr. Ketan Dhatariya

Excellent Diabetes UK conference: chairing,presenting on older adults and dementia, catching up with friends & making plans for the future! A great conference 🙏🏽 Dr “Jason” Wui Hang Cheung Sarah Alicea Prof Kamlesh Khunti Giuseppe Maltese hilarynathan Sarah Gregory Srikanth Bellary Zehra Yonel

Realigning #diabetes regimens in #olderadults: a 4S Pathway to guide simplification and deprescribing strategies thelancet.com/journals/landi… #T1D #T2D #FREE to read with registration (also FREE)

2-year open label follow up from the EMPA-KIDNEY trial found that #empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. nejm.org/doi/full/10.10…

Five-year trajectories of HbA1c in newly diagnosed people with T2 diabetes HbA1c trajectories worse in ethnic minority and people with young onset diabetes Our paper led by Anatu & Mohammad Ali dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

𝗖. 𝗛. 𝗔. 𝗠. 𝗣. 𝗜. 𝗢. 𝗡. 𝗦! 🇮🇳🏆 🏆 🏆 The Rohit Sharma-led #TeamIndia are ICC #ChampionsTrophy 2025 𝙒𝙄𝙉𝙉𝙀𝙍𝙎 👏 👏 Take A Bow! 🙌 🙌 #INDvNZ | #Final | Rohit Sharma

Frailty in Older Adults. NEJM 2024;391:538-48. #Geriatrics #Frailty #Olderadults

In type 2 diabetes (T2D), frailty can be improved & the progression from pre-frailty to frailty can be prevented. The MID-Frail study provides new insights into the adoption of preventive strategies aimed at disability prevention in frail older people w/ T2D. via The Journal of Nutrition, Health & Aging

ESSENCE Trial NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis, Improved liver histologic results nejm.org/doi/10.1056/NE…

Tirzepatide superior as Compared with Semaglutide for the Treatment of Obesity | SURMONT 5 nejm.org/doi/full/10.10…

Frailty: implications for clinical practice and public health. Lancet 2019; 394: 1365–75. via The Lancet

SGLT2 inhibitors reduce the risk of delirium and death in patients with type 2 diabetes, outperforming metformin in real-world data. ADA Professional Publications Read Here➡️ diabetesjournals.org/care/lookup/do…

📌 At #ADA2025 Once-weekly insulin efsitora alfa versus once-daily insulin glargine in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a randomised clinical trial hubs.li/Q03s_L--0 American Diabetes Association

Presented at #ADASciSessions: In QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results:

Frailty is the leading geriatric syndrome and remains poorly understood worldwide. The new The Lancet Commission calls for urgent action to reorient public health, clinical practice & policy to prevent & better manage frailty across the life course.